GNTA.OB...Sector: Healthcare...Industry: Biotechnology & Drugs

[gmarc66]

So is there no hope for this one to reach further highs tomorrow or in the near future?

thanks,

julia

[setravis]

company reported earnings of $14 million, or 15 cents a share, for the first quarter, up from its year-ago loss of $12.5 million, or 16 cents a share. Revenue jumped to $18.5 million in the latest three months from $1.7 million in the same period a year earlier. The company said the performance reflects acceleration of its recognition of deferred revenue following the termination of collaboration agreements related to its Genasense injection with Sanofi-Aventis.

[eliteG]

So is there no hope for this one to reach further highs tomorrow or in the near future?

thanks,

julia

Hi julia, from the closing chart it looks very bullish to me. 

Hope this makes sense(sometimes I don't  )
The chart shows a narrowing range(fluctuation) in the stock which translates to consolidation(the triangle) which can be looked on as an energy buildup.  Then what got my attention is it showed strength(broke the consolidation) with volume.

[gmarc66]

Thats great to hear eliteg!

I bought some yesterday at 1.24 x 500 shares.  There was alot of continued movement at and around that price for most of the afternoon...so, i hung on to it.
I can't read charts..so i appreciate ur imput greatly.

Also, Setravis added some information which is great...which seems to sound positive..thank you too.

thanks very much for your help! appreciate it.
good luck on your trades today!
julia

[setravis]

Hot in the pre-market.....
+32.03%....volume @ 1,708,817

[setravis]

BERKELEY HEIGHTS, N.J., Sept 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Genta Incorporated (GNTA, Trade) today announced the presentation of results from extended follow-up of patients enrolled in the Company's Phase 3 randomized trial of Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In addition to the previously announced significant increase in major response (the trial's primary endpoint), the new data show significantly longer remission duration and significantly lower risk of relapse. The data were presented in New York at meetings of the International World Congress on CLL and also at the First Annual Meeting of the Oligonucleotide Therapeutic Society. Genta has initiated a New Drug Application for accelerated approval of Genasense in CLL. The Company has requested a meeting with the Food and Drug Administration to discuss plans for a confirmatory post-approval study.

In the Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide (Flu/Cy) chemotherapy with or without Genasense. The trial achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR/nPR) (17% vs. 7%, respectively; P=0.025).

To date, 6 of the 8 patients (75%) who achieved CR/nPR with chemotherapy alone have relapsed compared with 5 of 20 patients (25%) in the Genasense treatment group. The median duration of CR/nPR was 22 months in the chemotherapy alone group; the median has not been reached in the Genasense group (P=0.03). All CR/nPR responses have been "durable" (i.e., exceeding 6 months duration).

"Extended followup has shown that most patients treated with chemotherapy alone have relapsed, whereas the remissions achieved by adding Genasense are continuing to prove quite durable," commented Dr. Kanti Rai, the trial's Principal Investigator. "These emerging differences have translated into real clinical benefit for patients."

"These new data provide important supportive evidence of the substantial clinical benefit for patients who receive Genasense in addition to standard chemotherapy for their disease," commented Dr. Loretta Itri, President and Chief Medical Officer of Genta. "The NDA submission process remains on track for completion later this year, and we look forward to our discussion with FDA regarding our Phase 4 study proposal."

Safety

Grade 3 or Grade 4 adverse events that occurred during treatment or within 30 days from last treatment in an increased percentage of patients in the Genasense group included, but were not limited to, thrombocytopenia, nausea, and intravenous-catheter complications. Adverse events resulted in discontinuation of therapy in an equal percentage of patients in both groups. Nine patients in the Genasense group and 5 patients in the chemotherapy-alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and "cytokine release syndrome." Other safety information from the trial can be accessed at: http://www.genta.com/Genta/InvestorRelation/2004/press_20041206.html .

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer. Genasense has received both Orphan Drug and Fast Track designations by FDA in CLL. The Company plans to seek "Accelerated Approval" for Genasense in CLL. Accelerated Approval requires the Company to conduct a confirmatory study in CLL, and Genta plans to discuss the design of this study with FDA.

About Chronic Lymphocytic Leukemia

CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. For more information about CLL, visit http://www.leukemia-lymphoma.org .

About Genta

Genta Incorporated is a pharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection, the Company's lead compound from its oligonucleotide program is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com .

Genta Forward Looking Statement

This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.

SOURCE Genta Incorporated


Investor Relations, +1-908-286-3980, [email protected] 

http://www.prnewswire.com 

Copyright (C) 2005 PR Newswire. All rights reserved. ********************************************************************** As of Thursday, 09-15-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 08-08-2005 for GNTA @ $1.07. (C) 2005 Comtex News Network, Inc. All rights reserved.

[Adam]

Is this a buy today??

[setravis]

End of the day chart

[dwest718]

Some news for ya.  Srry I didnt put it up earlier:

http://biz.yahoo.com/ap/051019/genta_mover.html?.v=1
http://biz.yahoo.com/prnews/051019/nyw061.html?.v=25

You can read it for yourself but the first link talks about Genta's drug that helps increase the effectiveness of radiation treatment of colon cancer.  The second link is a more detailed description of what the product does and the cancer it treats.  Colon cancer is the third most common type of cancer so any treatment that makes it easier to cause remission will be big.  This can be seen by the jump after the announcement on an announcement of a few positive tests.

Earnings on Nov. 7th (Monday)... expectations are -.09.

[dwest718]

Here's one for y'all.  I'll try to get some news and fundamentals up and update my TA but I'll just put the chart up for now.  I think this thing is poised for a breakout.  MACD lookin pretty good, RSI isn't that bad, 50dma just crossed 200dma.  Put a stop loss in at $1.50 and watch it with me!  Check out this chart:

[dwest718]

There's your jump today.  7.5% and still has room to move.  Should run up tomorrow in expectations of earnings Monday.  I'll get the updated chart up when stockcharts.com comes back up.

I got one right!  The arrow is right under the pop today.  If we get good earnings we should have a pop of 10-15%.  Check out yahoo message boards to see expectations and how good earnings have to be to get a great result.  I'll post the link in a little while for those of you who need it.

[dwest718]

Here's that updated chart.  Tell me what y'all think.  I drew the resistance a little bit high.  The candle today actually pushed into/tested a pretty good resistance level today.

[nullzero]

GNTA is looking attractive at these prices... Looking at the chart looks like a reversal is coming. 200 DMA is about to approach and looks like it may bounce off it. RSI is about to touch 20 looking at the charts GNTA loves to bounce off at or around 20 RSI. Comparing the MACD the last huge rally pattern looks a like.

[wrangler]

Bought GNTA today @1.40
Applied for FDA approval of new cancer drug and showing an upward MACD trend. Had a conferance meeting this morning,haven'y heard it yet. Analysis is saying the Pharma sector should be a good sector for 2006 with new drugs in the pipeline.
AP
Genta Shares Climb on FDA Application
Thursday December 29, 11:02 am ET 
Genta Submits New Drug Application to FDA for Its Lead Anticancer Drug Candidate; Shares Rise

BERKELEY HEIGHTS, N.J. (AP) -- Genta Inc., a biopharmaceutical concern, said Thursday it finished filing a new drug application with Food and Drug Administration for its lead anticancer drug candidate, Genasense Injection.

The company's shares soared nearly 6 percent, or 7 cents, to $1.43 on the Nasdaq, where it has traded in a yearly range of 75 cents to $1.98.

Genta asks that Genasense, or oblimersen sodium, plus fludarabine and cyclophosphamide be used as treatment for patients with relapsed or refractory chronic lymphocytic leukemia. The potentially fatal disease, which affects more than 60,000 Americans, stems from a problem in the lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

The application was submitted for "fast track" and "accelerated approval," programs, designed to expedite federal review for drugs that address an unmet medical need.

If selected for priority review, Genta may receive approval within six months of the filing date.





   

[akclide]

I was in yesterday 1.41.I think it deserves a price between 1.6-1.7 short term.Conf. call will tell us more but it is not till the 4th.Goodluck AK